A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

This study has been terminated.
(Unable to enroll due to criteria for stable baseline pain)
Sponsor:
Collaborator:
Teva Pharmaceuticals USA
Information provided by (Responsible Party):
OncoGenex Technologies
ClinicalTrials.gov Identifier:
NCT01083615
First received: February 26, 2010
Last updated: February 11, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to determine if the addition of study drug (custirsen) can provide durable pain palliation for castrate resistant prostate cancer patients receiving docetaxel retreatment or cabazitaxel as a second line therapy.


Condition Intervention Phase
Castrate-Resistant Prostate Cancer
Hormone Refractory Prostate Cancer
Drug: custirsen sodium
Drug: Isotonic, 0.9% sodium chloride
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer

Resource links provided by NLM:


Further study details as provided by OncoGenex Technologies:

Primary Outcome Measures:
  • To ascertain whether the investigational arm has a greater proportion of patients with durable pain palliation as compared to the control arm. [ Time Frame: 3 to 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To ascertain whether patients randomized to the investigational arm have a longer time to pain progression as compared to patients randomized to the control arm. [ Time Frame: 6 months. ] [ Designated as safety issue: No ]
  • Safety [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    Comparison of treatment arms with respect to the incidence of serious adverse events and the incidence of grade 3 or higher adverse events.


Enrollment: 14
Study Start Date: March 2010
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: custirsen
An antisense oligonucleotide that blocks production of clusterin.
Drug: custirsen sodium

Dose = 640 mg total dose. Study treatment starts with a Loading Dose Period ( 1 week) during which three infusions of study agent (custirsen or placebo) will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel on a 21-day cycle with weekly study agent (custirsen or placebo) infusions on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.

Patients will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol.

Other Name: OGX-011
Placebo Comparator: Isotonic, 0.9% sodium chloride Drug: Isotonic, 0.9% sodium chloride

Dose = 640 mg total dose. Study treatment starts with a Loading Dose Period ( 1 week) during which three infusions of study agent (custirsen or placebo) will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel on a 21-day cycle with weekly study agent (custirsen or placebo) infusions on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.

Patients will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol.


Detailed Description:

This is a randomized, double-blind, placebo-controlled, multicenter, international trial enrolling patients with metastatic CRPC who had a response to first-line docetaxel therapy and have prostate cancer-related pain with progression of disease. The intended intervention is second-line treatment with docetaxel retreatment or cabazitaxel plus study agent, where custirsen is to be administered in the investigational arm and placebo is to be administered in the control arm.

Selection of the chemotherapy (docetaxel re-treatment or cabazitaxel) is to be determined by the treating physician, based on the patient's first-line response.

The study will primarily assess pain and analgesic use for evaluation of durable pain palliation in response to study treatment. Pain and analgesic use will be obtained via a 3rd party contact center (direct contact with patient).

Study treatment starts with a Loading Dose Period during which three infusions of study agent (custirsen vs. placebo) will be administered. Following the Loading Dose Period, study treatment will consist of docetaxel or cabazitaxel on a 21-day cycle with weekly study agent (custirsen vs. placebo) infusions on Day 1, 8 and 15 of each 21-day cycle and oral prednisone BID.

Patients will continue study treatment until pain progression, unacceptable toxicity, completion of 10 cycles or other specific criteria for withdrawal identified in the protocol. If study treatment is completed or discontinued prior to pain progression, 6-day assessments will continue every 3 weeks until pain progression is documented. Follow-up after study treatment will occur for safety parameters for 3 weeks after the last study agent infusion in all patients. Survival status updates are to be reported every 12 weeks following documentation of pain progression. The amount of time that patients remain on the study will vary; but the average survival of these patients who receive second line taxane treatment is expected to be 14 to 15 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Age ≥ 18 years on the date of consent.
  2. Histological or cytological diagnosis of adenocarcinoma of the prostate.
  3. Metastatic disease at screening on a chest, abdomen or pelvic CT or bone scan.
  4. Concurrent pain and analgesic use that is viewed by the Investigator to be related to prostate cancer.
  5. Received at least 4 cycles of prior docetaxel-based first-line chemotherapy for metastatic disease based on a q3 week schedule of docetaxel. Patients treated on a weekly or alternate schedule for first-line docetaxel must have received an accumulated dose of docetaxel of at least 300 mg/M2.
  6. Current progressive disease during or after completing first-line docetaxel treatment.
  7. Baseline laboratory values at screening visit within protocol defined limits.
  8. Must be willing to continue primary androgen suppression with luteinizing hormone releasing hormone (LHRH) analogues throughout the study, if not treated with bilateral orchiectomy.
  9. Adequate bone marrow function.
  10. Karnofsky score ≥ 70% at screening visit.
  11. At least 21 days have passed since completing radiotherapy at the time of randomization.
  12. At least 21 days have passed since completing any cytotoxic agent or investigational agent given in combination with the docetaxel-based first-line therapy, including ASOs (except custirsen which is an exclusion criterion), at the time of randomization.
  13. Has recovered from all therapy related toxicity to ≤ grade 2 (except alopecia, anemia and any signs or symptoms of androgen deprivation therapy).
  14. Patient can tolerate a starting dose of docetaxel of 75 mg/M2 or cabazitaxel at 25 mg/M2.
  15. Patient must have remained on the same bisphosphonate or denosumab usage for a minimum of 12 weeks prior to randomization.
  16. Written informed consent must be obtained prior to any protocol-specific procedures being performed.

Exclusion Criteria

  1. More than two interruptions in first-line docetaxel therapy. An interruption will be defined as more than 6 weeks between doses.
  2. Life expectancy less than 12 weeks.
  3. Previously participated in any clinical trial evaluating custirsen.
  4. Received any other cytotoxic chemotherapy as a second-line treatment after first-line docetaxel-based therapy.
  5. Not on any opioid analgesic regimen for their prostate cancer-related pain.
  6. Receiving more than one drug within each of the separate categories of long-acting opioid, short-acting opioid, and non-opioid.
  7. Receiving any analgesic specified in the protocol as unacceptable for this study.
  8. Planned concomitant participation in another clinical trial of an experimental agent, vaccine or device. Concomitant participation in observational studies is acceptable.
  9. Inability to communicate and read in English, Spanish or French.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01083615

  Show 33 Study Locations
Sponsors and Collaborators
OncoGenex Technologies
Teva Pharmaceuticals USA
Investigators
Principal Investigator: Tomasz M Beer, M.D. Oregon Health and Science University
Principal Investigator: Sebastien J Hotte, M.D. Juravinski Cancer Centre, McMaster University
Principal Investigator: Karim Fizazi, M.D., Ph.D. Institut Gustave Roussy, University of Paris
  More Information

No publications provided

Responsible Party: OncoGenex Technologies
ClinicalTrials.gov Identifier: NCT01083615     History of Changes
Other Study ID Numbers: OGX-011-10
Study First Received: February 26, 2010
Last Updated: February 11, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by OncoGenex Technologies:
CRPC patients with cancer related pain
CRPC
HRPC

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on August 20, 2014